Omid Hamid
Angeles Clinic and Research Institute
3 papers in the Anchorcite directory, published between 2012 and 2015, cited 20,382 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- T-cell and B-cell Immunology · 1 paper
- Immunotherapy and Immune Responses · 1 paper
- Lung Cancer Treatments and Mutations · 1 paper
- Lung Cancer Research Studies · 1 paper
- Cutaneous Melanoma Detection and Management · 1 paper
Frequent co-authors
- Julie Renee Brahmer · 1 paper
- Scott S. Tykodi · 1 paper
- Laura Q.M. Chow · 1 paper
- Wen‐Jen Hwu · 1 paper
- Suzanne Louise Topalian · 1 paper
- Patrick Hwu · 1 paper
- Charles G. Drake · 1 paper
- Luis H. Camacho · 1 paper
Papers
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations
BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…
Metadata from OpenAlex (CC0).